Pacific Biosciences of California (PACB) 10-Q 8 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	1-May-14
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'PACB	'
Entity Registrant Name	'PACIFIC BIOSCIENCES OF CALIFORNIA, INC.	'
Entity Central Index Key	'0001299130	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	70,495,251

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$41,261	$26,362
Investments	77,475	86,166
Accounts receivable	3,383	2,746
Inventory, net	8,301	10,050
Prepaid expenses and other current assets	1,642	1,135
Total current assets	132,062	126,459
Property and equipment, net	8,492	9,236
Other long-term assets	486	490
Total assets	141,040	136,185
Current liabilities	'	'
Accounts payable	3,926	1,717
Accrued expenses and other current liabilities	7,678	9,797
Deferred service revenue, current	3,904	4,046
Deferred contractual revenue, current	6,785	6,785
Facility financing obligation, current	220	210
Total current liabilities	22,513	22,555
Deferred service revenue, non-current	918	518
Deferred contractual revenue, non-current	24,823	26,519
Facility financing obligation, non-current	2,345	2,403
Deferred rent and other long-term liabilities	842	1,114
Notes payable	13,525	13,347
Financing derivative	549	549
Total liabilities	65,515	67,005
Commitments and contingencies	'	'
Stockholders' equity	'	'
Preferred Stock, $0.001 par value Authorized 50,000 shares; No shares issued or outstanding	'	'
Common Stock, $0.001 par value: Authorized 1,000,000 shares; Issued and outstanding 70,472 shares at March 31, 2014 and 66,275 shares at December 31, 2013, respectively	70	66
Additional paid-in-capital	709,636	684,413
Accumulated other comprehensive income	18	14
Accumulated deficit	-634,199	-615,313
Total stockholders' equity	75,525	69,180
Total liabilities and stockholders' equity	$141,040	$136,185

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Condensed Consolidated Balance Sheets [Abstract]	'	'
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	50,000,000	50,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	1,000,000,000	1,000,000,000
Common Stock, shares issued	70,472,000	66,275,000
Common Stock, shares outstanding	70,472,000	66,275,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Operations And Comprehensive Loss (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenue:	'	'
Product revenue	$7,865	$3,833
Service and other revenue	2,081	1,745
Contractual revenue	1,696	'
Total revenue	11,642	5,578
Cost of Revenue:	'	'
Cost of product revenue	7,169	3,200
Cost of service and other revenue	1,797	1,448
Total cost of revenue	8,966	4,648
Gross profit	2,676	930
Operating Expense:	'	'
Research and development	11,771	11,983
Sales, general and administrative	9,150	9,554
Total operating expense	20,921	21,537
Operating loss	-18,245	-20,607
Interest expense	-686	-426
Other income (expense), net	45	-71
Net loss	-18,886	-21,104
Other comprehensive income (loss):	'	'
Unrealized gain (loss) on investments	4	-19
Comprehensive loss	($18,882)	($21,123)
Net loss per share:	'	'
Basic and diluted net loss per share	($0.28)	($0.37)
Shares used in computing basic and diluted net loss per share	67,861	57,372

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities	'	'
Net loss	($18,886)	($21,104)
Adjustments to reconcile net loss to net cash used in operating activities	'	'
Depreciation	1,221	1,493
Amortization of debt discount and financing costs	182	89
Stock-based compensation	2,270	2,746
Other items	'	32
Changes in assets and liabilities	'	'
Accounts receivable	-637	813
Inventory	1,749	-607
Prepaid expenses and other assets	-487	431
Accounts payable	2,209	22
Accrued expenses and other current liabilities	-2,119	-779
Deferred service revenue	258	-423
Deferred contractual revenue	-1,696	'
Deferred rent and other long-term liabilities	-320	-288
Net cash used in operating activities	-16,256	-17,575
Cash flows from investing activities	'	'
Purchase of property and equipment	-477	-297
Purchase of investments	-36,515	-42,466
Maturities of investments	45,190	37,180
Net cash provided by (used in) investing activities	8,198	-5,583
Cash flows from financing activities	'	'
Proceeds from issuance of common stock from equity plans	2,311	1,235
Proceeds from issuance of common stock from at-the-market equity offering, net of issuance costs	20,646	8,655
Proceeds from issuance of Facility Agreement, net of issuance costs	'	19,766
Net cash provided by financing activities	22,957	29,656
Net decrease in cash and cash equivalents	14,899	6,498
Cash and cash equivalents at beginning of period	26,362	46,540
Cash and cash equivalents at end of period	$41,261	$53,038

Overview

Overview	3 Months Ended
	Mar. 31, 2014
Overview [Abstract]	'
Overview	'
	NOTE 1. OVERVIEW
	Pacific Biosciences of California, Inc., (“Pacific Biosciences”, the “Company”, “we”, “us”) has commercialized the PacBio RS II Sequencing System to help scientists solve genetically complex problems. Based on our novel Single Molecule, Real-Time (SMRT) technology, our products enable scientists to increase their understanding of biological systems through targeted sequencing and insight into genetic variations.
	The names “Pacific Biosciences,” “PacBio,” “SMRT,” “SMRTbell” and our logo are our trademarks.

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Summary Of Significant Accounting Policies [Abstract]	'
Summary Of Significant Accounting Policies	'
	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements (“Financial Statements”) of Pacific Biosciences of California, Inc. and its wholly-owned subsidiaries have been prepared on a consistent basis with the December 31, 2013 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. Certain prior year amounts in the Financial Statements and notes thereto have been reclassified to conform to the current year’s presentation. The Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, omit certain information and footnote disclosures necessary to present the statements in accordance with U.S. generally accepted accounting principles (“GAAP”). These Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and Notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. The results of operations for the three-month period ended March 31, 2014 are not necessarily indicative of the results to be expected for the entire fiscal year or any future periods.
	Use of Estimates
	The preparation of Financial Statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying Notes to the Financial Statements. Our estimates include, but are not limited to, the valuation of inventory, financing derivative, long-term notes, and equity grants and related stock-based compensation, as well as the assumptions and estimates used to allocate proceeds received in revenue, debt and equity transactions which may affect revenue recognition and interest expense. Actual results could differ materially from these estimates.
	Reclassifications
	Certain prior period amounts in the condensed consolidated statements of operations and comprehensive loss have been reclassified to conform to current period presentation. We reclassified $0.3 million of Grant revenue to Service and other revenue for the three-month period ended March 31, 2013. Such reclassification did not impact our net loss or financial position.
	Fair Value of Financial Instruments
	Assets and liabilities measured at fair value on a recurring basis
	The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of March 31, 2014 and December 31, 2013, respectively:
	(in thousands)	31-Mar-14									31-Dec-13
		Level 1			Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash and money market funds	$	19,885		$	—	$	—	$	19,885	$	12,963	$	—	$	—	$	12,963
	Commercial paper		—			21,376		—		21,376		—		13,399		—		13,399
	Total cash and cash equivalents		19,885			21,376		—		41,261		12,963		13,399		—		26,362
	Investments:
	Commercial paper		—			48,578		—		48,578		—		61,264		—		61,264
	Corporate debt securities		—			8,599		—		8,599		—		8,629		—		8,629
	Asset backed securities		—			20,298		—		20,298		—		16,273		—		16,273
	Total investments		—			77,475		—		77,475		—		86,166		—		86,166
	Total assets measured at fair value	$	19,885		$	98,851	$	—	$	118,736	$	12,963	$	99,565	$	—	$	112,528
	Liabilities
	Financing derivative	$	—		$	—	$	549	$	549	$	—	$	—	$	549	$	549
	Total liabilities measured at fair value	$	—		$	—	$	549	$	549	$	—	$	—	$	549	$	549
	All of our cash deposits and money market funds are classified within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. Our investments are classified as Level 2 instruments based on market pricing and other observable inputs. None of our investments are classified within Level 3 of the fair value hierarchy.
	During the three-month periods ended March 31, 2014 and 2013, realized gains and losses on the sale of investments were immaterial and there were no material impairments of our investments.
	The fair value of the Financing Derivative liability (as defined in Note 6. Debt) resulting from the debt facility we entered into during the first quarter of 2013 was determined using Level 3 inputs, or significant unobservable inputs.  Please refer to Note 6. Debt for a detailed description on the valuation approach. Changes to the fair value of the Financing Derivative are recorded in “Other income (expense), net” in the condensed consolidated statements of operations and comprehensive loss. The fair value of the Finance Derivative was $0.5 million at December 31, 2013 and there was no change to the fair value of the Financial Derivative at March 31, 2014.
	During the three-month period ended March 31, 2014 there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and valuation techniques did not change compared to established practice.
	Financial assets and liabilities not measured at fair value on a recurring basis
	The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities approximate fair value due to their short maturities. The carrying value of our facility financing obligation approximates fair value due to the time to maturity and prevailing market rates.
	We determined the fair value of the Notes (as defined in Note 6. Debt) from the debt facility using Level 3 inputs, or significant unobservable inputs. The value of the Notes was determined by comparing the difference between the fair value of the Notes with and without the Financing Derivative by calculating the respective present values from future cash flows using a 20.4% weighted average market yield. The estimated fair value and carrying value of the Notes are as follows (in thousands):
		31-Mar-14					31-Dec-13
		Fair Value			Carrying Value		Fair Value		Carrying Value
	Long-term notes payable	$	14,551		$	13,525	$	14,551	$	13,347
	Net Loss per Share
	The following table presents the computation of our basic and diluted net loss per share (in thousands, except per share amounts):
		Three-Month Periods Ended March 31,
		2014			2013
	Net loss per share
	Numerator:
	Net loss	$	-18,886		$	-21,104
	Denominator:
	Weighted average shares used in computation of basic and diluted net loss per share		67,861			57,372
	Basic and diluted net loss per share	$	-0.28		$	-0.37
	The following were excluded from the computation of our diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:
		March 31,
	(in thousands)	2014		2013
	Options outstanding	15,714		13,741
	Warrants to purchase common stock	5,500		5,504

Contractual_Revenue

Contractual Revenue	3 Months Ended
	Mar. 31, 2014
Contractual Revenue [Abstract]	'
Contractual Revenue	'
	NOTE 3. CONTRACTUAL REVENUE
	During September 2013 we entered into a Development, Commercialization and License Agreement (the “Roche Agreement”) with F. Hoffman-La Roche Ltd (“Roche”), pursuant to which we account for, and recognize to revenue, the up-front payment using the proportional performance method over the periods in which the delivery of elements of the agreement occurs. We recognize revenue using a straight line convention over the service periods of the deliverables as this method approximates our performance of services pursuant to the contract. Out of $35.0 million upfront cash payment received, $1.7 million has been recognized as revenue for the three-month period ended March 31, 2014 and $31.6 million remains deferred as of March 31, 2014 and will be recognized as revenue over the estimated obligation periods.
	In addition to the non-contingent deliverables above, the Roche Agreement includes contingent deliverables relating to the receipt of additional payments totaling $40.0 million upon the achievement of certain development milestones. Based on ASC Topic 605-28, Revenue Recognition — Milestone Method, we recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is considered substantive in its entirety. Milestones are considered substantive if the consideration earned from the achievement of the milestone (i) is consistent with performance required to achieve the milestone or the increase in value to the delivered item, (ii) relates solely to past performance and (iii) is reasonable relative to all of the other deliverables and payments within the arrangement. The milestone payments of $40.0 million will be recognized as revenue in their entirety upon our achievement of each substantive milestone.  No milestone revenue was recognized as of March 31, 2014.

Cash_Cash_Equivalents_And_Inve

Cash, Cash Equivalents And Investments	3 Months Ended
	Mar. 31, 2014
Cash, Cash Equivalents And Investments [Abstract]	'
Cash, Cash Equivalents And Investments	'
	NOTE 4. CASH, CASH EQUIVALENTS AND INVESTMENTS
	The following table summarizes our investments as of March 31, 2014 and December 31, 2013 (in thousands):
		31-Mar-14
				Gross		Gross
		Amortized		unrealized		unrealized		Fair
		Cost		gains		losses		Value
	Cash and cash equivalents:
	Cash and money market funds	$	19,885	$	—	$	—	$	19,885
	Commercial paper		21,375		1		—		21,376
	Total cash and cash equivalents		41,260		1		—		41,261
	Investments:
	Commercial paper		48,575		4		-1		48,578
	Corporate debt securities		8,589		13		-3		8,599
	Asset backed securities		20,294		9		-5		20,298
	Total investments		77,458		26		-9		77,475
	Total cash, cash equivalents and investments	$	118,718	$	27	$	-9	$	118,736
		31-Dec-13
				Gross		Gross
		Amortized		unrealized		unrealized		Fair
		Cost		gains		losses		Value
	Cash and cash equivalents:
	Cash and money market funds	$	12,963	$	—	$	—	$	12,963
	Commercial paper		13,398		1		—		13,399
	Total cash and cash equivalents		26,361		1		—		26,362
	Investments:
	Commercial paper		61,252		13		-1		61,264
	Corporate debt securities		8,620		12		-3		8,629
	Asset backed securities		16,281		2		-10		16,273
	Total investments		86,153		27		-14		86,166
	Total cash, cash equivalents and investments	$	112,514	$	28	$	-14	$	112,528
	The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of March 31, 2014:
	(in thousands)	Fair Value
	Due in one year or less	$	71,947
	Due after one year through 5 years		26,904
	Total investments in debt securities	$	98,851
	Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.

Balance_Sheet_Components

Balance Sheet Components	3 Months Ended
	Mar. 31, 2014
Balance Sheet Components [Abstract]	'
Balance Sheet Components	'
	NOTE 5. BALANCE SHEET COMPONENTS
	Inventory, net
	As of March 31, 2014 and December 31, 2013, our inventory, net, consisted of the following components:
		March 31,		December 31,
	(in thousands)	2014		2013
	Purchased materials, net	$	2,644	$	3,019
	Work in process, net		4,003		4,012
	Finished goods, net		1,654		3,019
	Inventory, net	$	8,301	$	10,050

Debt

Debt	3 Months Ended
	Mar. 31, 2014
Debt [Abstract]	'
Debt	'
	NOTE 6. DEBT
	Pursuant to a Facility Agreement (the “Facility Agreement”) we entered into with entities affiliated with Deerfield Management Company, L.P. (collectively, “Deerfield”) in February 2013, we issued to Deerfield promissory notes in the aggregate principal amount of $20.5 million (the “Notes”). The Notes bear simple interest at a rate of 8.75% per annum, payable quarterly in arrears commencing on April 1, 2013. The Facility Agreement also contains various representations and warranties, and affirmative and negative covenants, customary for financings of this type, including restrictions on the ability of the Company and its subsidiaries to incur additional indebtedness or liens on its assets, except as permitted under the Facility Agreement. In addition, we are required to maintain consolidated cash and cash equivalents on the last day of each calendar quarter of not less than $2.0 million. As security for our repayment of our obligations under the Facility Agreement, we granted to Deerfield a security interest in substantially all of our property and interests in property.
	Notes
	The Notes and Warrants were initially recorded at a value of $14.1 million and $6.4 million, respectively, based upon the relative fair value allocation of the $20.5 million of proceeds. Additionally, facility fees and other issuance costs were allocated based on the relative fair value of the Facility and the Warrants.  The amount allocated to the Notes was then reduced by the $1.0 million fair value of the Financing Derivative, such that the Financing Derivative was recorded at its absolute fair value.  As a result, the carrying value of the Notes at the inception of the debt was $12.8 million, resulting in an original issue discount of $7.7 million. The discount is being accreted to the $20.5 million face value of the Notes over the expected maturity period of seven years using the effective interest method, with an effective interest rate of 20.6%.
	Warrants
	In connection with the execution of the Facility Agreement, in February 2013 we issued to Deerfield warrants to purchase an aggregate of 5,500,000 shares of common stock immediately exercisable at an exercise price per share initially equal to $2.63. We recorded the $6.4 million fair value of the warrants in “Additional paid-in capital” line of the condensed consolidated balance sheets in 2013. As of March 31, 2014, we had outstanding warrants to purchase an aggregate of 5,500,000 shares of common stock.
	Financing Derivative
	A number of features embedded in the Notes to the Facility Agreement required accounting for as a derivative, including the indemnification of certain withholding taxes and the acceleration of debt upon (a) a qualified financing, (b) an Event of Default, (c) a Major Transaction, and (d) the exercise of the Warrant via offset to debt principal. These features represent a single derivative (the “Financing Derivative”) that was bifurcated from the debt instrument and accounted for as a liability at fair value, with changes in fair value between reporting periods recorded in other income (expense), net. The value of the Financing Derivative was determined by comparing the difference between the fair value of the Notes with and without the Financing Derivative by calculating the respective present values from future cash flows using a 20.4% weighted average market yield. The fair value of the Financing Derivative as of both March 31, 2014 and December 31, 2013 was $0.5 million.

Stockholders_Equity_And_ShareB

Stockholders' Equity And Share-Based Compensation	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity And Share-Based Compensation [Abstract]	'
Stockholders' Equity And Share-Based Compensation	'
	NOTE 7. STOCKHOLDERS’ EQUITY AND SHARE-BASED COMPENSATION
	Equity Offering
	For the three-month period ended March 31, 2014,  we issued 3.0 million shares of our common stock at an average price of $7.12 per share through our “at-the-market” offering, resulting in net proceeds of $20.6 million. Under our current “at-the-market” offering program, $17.9 million of common stock remain available for future sales; however, we are not obligated to make any sales under this program.
	Equity Plans
	As of March 31, 2014, we had three active equity compensation plans, the 2010 Equity Incentive Plan, or 2010 Plan, the 2010 Outside Director Equity Incentive Plan, or 2010 Director Plan, and the 2010 Employee Stock Purchase Plan, or ESPP.
	The following table summarizes stock option activity for all stock option plans for the three-month period ended March 31, 2014 (in thousands, except per share amounts):
				Stock Options Outstanding
								Weighted
		Shares available		Number				average
		for grant		of shares		Exercise price		exercise price
	Balances, December 31, 2013	3,912		14,070		$	0.20 – 16.00	$	4.81
	Additional shares reserved	3,977
	Options granted	-1,898		1,898			5.98 – 7.05		6.61
	Options exercised	—		-164			0.70 – 6.96		2.96
	Options canceled	90		-90			1.16 – 12.74		6.70
	Balances, March 31, 2014	6,081		15,714		$	0.20 – 16.00	$	5.04
	As of March 31, 2014, 276,903 shares of our common stock remain available for issuance under our ESPP. Shares issued under the ESPP totaled 1,048,604 and 733,111 shares during the three-month periods ended March 31, 2014 and 2013, respectively.
	Stock-based Compensation
	Total stock-based compensation expense consists of the following (in thousands):
		Three-Month Periods Ended March 31,
		2014			2013
	Cost of revenue	$	141		$	136
	Research and development		886			1,217
	Sales, general and administrative		1,243			1,393
	Total stock-based compensation expense	$	2,270		$	2,746
	We estimated the fair value of employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following weighted average assumptions:
		Three-Month Periods Ended March 31,
	Stock Option	2014		2013
	Expected term in years	6.1		6.1
	Expected volatility	70%		65%
	Risk-free interest rate	1.90%		1.10%
	Dividend yield	—		—
	We estimate the value of the employee stock purchase rights on the grant date using the Black-Scholes option pricing model. The fair value of ESPP was estimated using the following assumptions:
		Three-Month Periods Ended March 31,
	ESPP	2014		2013
	Expected term in years	0.5-2.0		0.5-2.0
	Expected volatility	70%		70%
	Risk-free interest rate	0.1%-0.3%		0.1%-0.3%
	Dividend yield	—		—

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policy)	3 Months Ended
	Mar. 31, 2014
Summary Of Significant Accounting Policies [Abstract]	'
Basis Of Presentation	'
	Basis of Presentation
	In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements (“Financial Statements”) of Pacific Biosciences of California, Inc. and its wholly-owned subsidiaries have been prepared on a consistent basis with the December 31, 2013 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. Certain prior year amounts in the Financial Statements and notes thereto have been reclassified to conform to the current year’s presentation. The Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, omit certain information and footnote disclosures necessary to present the statements in accordance with U.S. generally accepted accounting principles (“GAAP”). These Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and Notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. The results of operations for the three-month period ended March 31, 2014 are not necessarily indicative of the results to be expected for the entire fiscal year or any future periods.
Use Of Estimates	'
	Use of Estimates
	The preparation of Financial Statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying Notes to the Financial Statements. Our estimates include, but are not limited to, the valuation of inventory, financing derivative, long-term notes, and equity grants and related stock-based compensation, as well as the assumptions and estimates used to allocate proceeds received in revenue, debt and equity transactions which may affect revenue recognition and interest expense. Actual results could differ materially from these estimates.
Reclassifications	'
	Reclassifications
	Certain prior period amounts in the condensed consolidated statements of operations and comprehensive loss have been reclassified to conform to current period presentation. We reclassified $0.3 million of Grant revenue to Service and other revenue for the three-month period ended March 31, 2013. Such reclassification did not impact our net loss or financial position.
Fair Value Of Financial Instruments	'
	Fair Value of Financial Instruments
	Assets and liabilities measured at fair value on a recurring basis
	The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of March 31, 2014 and December 31, 2013, respectively:
	(in thousands)	31-Mar-14									31-Dec-13
		Level 1			Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash and money market funds	$	19,885		$	—	$	—	$	19,885	$	12,963	$	—	$	—	$	12,963
	Commercial paper		—			21,376		—		21,376		—		13,399		—		13,399
	Total cash and cash equivalents		19,885			21,376		—		41,261		12,963		13,399		—		26,362
	Investments:
	Commercial paper		—			48,578		—		48,578		—		61,264		—		61,264
	Corporate debt securities		—			8,599		—		8,599		—		8,629		—		8,629
	Asset backed securities		—			20,298		—		20,298		—		16,273		—		16,273
	Total investments		—			77,475		—		77,475		—		86,166		—		86,166
	Total assets measured at fair value	$	19,885		$	98,851	$	—	$	118,736	$	12,963	$	99,565	$	—	$	112,528
	Liabilities
	Financing derivative	$	—		$	—	$	549	$	549	$	—	$	—	$	549	$	549
	Total liabilities measured at fair value	$	—		$	—	$	549	$	549	$	—	$	—	$	549	$	549
	All of our cash deposits and money market funds are classified within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. Our investments are classified as Level 2 instruments based on market pricing and other observable inputs. None of our investments are classified within Level 3 of the fair value hierarchy.
	During the three-month periods ended March 31, 2014 and 2013, realized gains and losses on the sale of investments were immaterial and there were no material impairments of our investments.
	The fair value of the Financing Derivative liability (as defined in Note 6. Debt) resulting from the debt facility we entered into during the first quarter of 2013 was determined using Level 3 inputs, or significant unobservable inputs.  Please refer to Note 6. Debt for a detailed description on the valuation approach. Changes to the fair value of the Financing Derivative are recorded in “Other income (expense), net” in the condensed consolidated statements of operations and comprehensive loss. The fair value of the Finance Derivative was $0.5 million at December 31, 2013 and there was no change to the fair value of the Financial Derivative at March 31, 2014.
	During the three-month period ended March 31, 2014 there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and valuation techniques did not change compared to established practice.
	Financial assets and liabilities not measured at fair value on a recurring basis
	The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities approximate fair value due to their short maturities. The carrying value of our facility financing obligation approximates fair value due to the time to maturity and prevailing market rates.
	We determined the fair value of the Notes (as defined in Note 6. Debt) from the debt facility using Level 3 inputs, or significant unobservable inputs. The value of the Notes was determined by comparing the difference between the fair value of the Notes with and without the Financing Derivative by calculating the respective present values from future cash flows using a 20.4% weighted average market yield. The estimated fair value and carrying value of the Notes are as follows (in thousands):
		31-Mar-14					31-Dec-13
		Fair Value			Carrying Value		Fair Value		Carrying Value
	Long-term notes payable	$	14,551		$	13,525	$	14,551	$	13,347
Net Loss Per Share	'
	Net Loss per Share
	The following table presents the computation of our basic and diluted net loss per share (in thousands, except per share amounts):
		Three-Month Periods Ended March 31,
		2014			2013
	Net loss per share
	Numerator:
	Net loss	$	-18,886		$	-21,104
	Denominator:
	Weighted average shares used in computation of basic and diluted net loss per share		67,861			57,372
	Basic and diluted net loss per share	$	-0.28		$	-0.37
	The following were excluded from the computation of our diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:
		March 31,
	(in thousands)	2014		2013
	Options outstanding	15,714		13,741
	Warrants to purchase common stock	5,500		5,504

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Summary Of Significant Accounting Policies [Abstract]	'
Summary Of Assets And Liabilities Measured At Fair Value Classified Based On Level Of Input	'
	(in thousands)	31-Mar-14									31-Dec-13
		Level 1			Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash and money market funds	$	19,885		$	—	$	—	$	19,885	$	12,963	$	—	$	—	$	12,963
	Commercial paper		—			21,376		—		21,376		—		13,399		—		13,399
	Total cash and cash equivalents		19,885			21,376		—		41,261		12,963		13,399		—		26,362
	Investments:
	Commercial paper		—			48,578		—		48,578		—		61,264		—		61,264
	Corporate debt securities		—			8,599		—		8,599		—		8,629		—		8,629
	Asset backed securities		—			20,298		—		20,298		—		16,273		—		16,273
	Total investments		—			77,475		—		77,475		—		86,166		—		86,166
	Total assets measured at fair value	$	19,885		$	98,851	$	—	$	118,736	$	12,963	$	99,565	$	—	$	112,528
	Liabilities
	Financing derivative	$	—		$	—	$	549	$	549	$	—	$	—	$	549	$	549
	Total liabilities measured at fair value	$	—		$	—	$	549	$	549	$	—	$	—	$	549	$	549
Estimated Fair Value And Carrying Value of Notes	'
		31-Mar-14					31-Dec-13
		Fair Value			Carrying Value		Fair Value		Carrying Value
	Long-term notes payable	$	14,551		$	13,525	$	14,551	$	13,347
Computation Of Basic And Diluted Net Loss Per Share	'
		Three-Month Periods Ended March 31,
		2014			2013
	Net loss per share
	Numerator:
	Net loss	$	-18,886		$	-21,104
	Denominator:
	Weighted average shares used in computation of basic and diluted net loss per share		67,861			57,372
	Basic and diluted net loss per share	$	-0.28		$	-0.37
Anti-dilutive Excluded From Computation Of Diluted Net Loss Per Share	'
		March 31,
	(in thousands)	2014		2013
	Options outstanding	15,714		13,741
	Warrants to purchase common stock	5,500		5,504

Cash_Cash_Equivalents_And_Inve1

Cash, Cash Equivalents And Investments (Tables)	3 Months Ended
	Mar. 31, 2014
Cash, Cash Equivalents And Investments [Abstract]	'
Summary Of Cash, Cash Equivalents And Investments	'
		31-Mar-14
				Gross		Gross
		Amortized		unrealized		unrealized		Fair
		Cost		gains		losses		Value
	Cash and cash equivalents:
	Cash and money market funds	$	19,885	$	—	$	—	$	19,885
	Commercial paper		21,375		1		—		21,376
	Total cash and cash equivalents		41,260		1		—		41,261
	Investments:
	Commercial paper		48,575		4		-1		48,578
	Corporate debt securities		8,589		13		-3		8,599
	Asset backed securities		20,294		9		-5		20,298
	Total investments		77,458		26		-9		77,475
	Total cash, cash equivalents and investments	$	118,718	$	27	$	-9	$	118,736
		31-Dec-13
				Gross		Gross
		Amortized		unrealized		unrealized		Fair
		Cost		gains		losses		Value
	Cash and cash equivalents:
	Cash and money market funds	$	12,963	$	—	$	—	$	12,963
	Commercial paper		13,398		1		—		13,399
	Total cash and cash equivalents		26,361		1		—		26,362
	Investments:
	Commercial paper		61,252		13		-1		61,264
	Corporate debt securities		8,620		12		-3		8,629
	Asset backed securities		16,281		2		-10		16,273
	Total investments		86,153		27		-14		86,166
	Total cash, cash equivalents and investments	$	112,514	$	28	$	-14	$	112,528
Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments	'
	(in thousands)	Fair Value
	Due in one year or less	$	71,947
	Due after one year through 5 years		26,904
	Total investments in debt securities	$	98,851

Balance_Sheet_Components_Table

Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2014
Balance Sheet Components [Abstract]	'
Components Of Inventory	'
		March 31,		December 31,
	(in thousands)	2014		2013
	Purchased materials, net	$	2,644	$	3,019
	Work in process, net		4,003		4,012
	Finished goods, net		1,654		3,019
	Inventory, net	$	8,301	$	10,050

Stockholders_Equity_And_ShareB1

Stockholders' Equity And Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Summary Of Stock Option Activity	'
				Stock Options Outstanding
								Weighted
		Shares available		Number				average
		for grant		of shares		Exercise price		exercise price
	Balances, December 31, 2013	3,912		14,070		$	0.20 – 16.00	$	4.81
	Additional shares reserved	3,977
	Options granted	-1,898		1,898			5.98 – 7.05		6.61
	Options exercised	—		-164			0.70 – 6.96		2.96
	Options canceled	90		-90			1.16 – 12.74		6.70
	Balances, March 31, 2014	6,081		15,714		$	0.20 – 16.00	$	5.04
Schedule Of Stock-Based Compensation Expense	'
		Three-Month Periods Ended March 31,
		2014			2013
	Cost of revenue	$	141		$	136
	Research and development		886			1,217
	Sales, general and administrative		1,243			1,393
	Total stock-based compensation expense	$	2,270		$	2,746
Schedule Of Fair Value Of Employee Stock Options	'
		Three-Month Periods Ended March 31,
	Stock Option	2014		2013
	Expected term in years	6.1		6.1
	Expected volatility	70%		65%
	Risk-free interest rate	1.90%		1.10%
	Dividend yield	—		—
ESPP [Member]	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Schedule Of Fair Value Of Employee Stock Options	'
		Three-Month Periods Ended March 31,
	ESPP	2014		2013
	Expected term in years	0.5-2.0		0.5-2.0
	Expected volatility	70%		70%
	Risk-free interest rate	0.1%-0.3%		0.1%-0.3%
	Dividend yield	—		—

Summary_Of_Significant_Account3

Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Reclassification from Grant revenue to Service and other revenue	'	$300,000	'
Impairment charges on investments	0	0	'
Liabilities measured at fair value	549,000	'	549,000
Fair value assets liabilities transfer between levels	0	'	'
Future cash flows weighted average market yield	20.40%	'	'
Financing Derivative [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Liabilities measured at fair value	$549,000	'	$549,000

Summary_Of_Significant_Account4

Summary Of Significant Accounting Policies (Summary Of Assets And Liabilities Measured At Fair Value Classified Based On Level Of Input) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets	'	'
Total assets measured at fair value	$118,736	$112,528
Liabilities	'	'
Total liabilities measured at fair value	549	549
Financing Derivative [Member]	'	'
Liabilities	'	'
Total liabilities measured at fair value	549	549
Cash And Cash Equivalents [Member]	'	'
Assets	'	'
Total cash and cash equivalents	41,261	26,362
Cash And Cash Equivalents [Member] | Cash And Money Market Funds [Member]	'	'
Assets	'	'
Total cash and cash equivalents	19,885	12,963
Cash And Cash Equivalents [Member] | Commercial Paper [Member]	'	'
Assets	'	'
Total cash and cash equivalents	21,376	13,399
Investments [Member]	'	'
Assets	'	'
Total investments	77,475	86,166
Investments [Member] | Commercial Paper [Member]	'	'
Assets	'	'
Total investments	48,578	61,264
Investments [Member] | Corporate Debt Securities [Member]	'	'
Assets	'	'
Total investments	8,599	8,629
Investments [Member] | Asset Backed Securities [Member]	'	'
Assets	'	'
Total investments	20,298	16,273
Level 1 [Member]	'	'
Assets	'	'
Total assets measured at fair value	19,885	12,963
Level 1 [Member] | Cash And Cash Equivalents [Member]	'	'
Assets	'	'
Total cash and cash equivalents	19,885	12,963
Level 1 [Member] | Cash And Cash Equivalents [Member] | Cash And Money Market Funds [Member]	'	'
Assets	'	'
Total cash and cash equivalents	19,885	12,963
Level 2 [Member]	'	'
Assets	'	'
Total assets measured at fair value	98,851	99,565
Level 2 [Member] | Cash And Cash Equivalents [Member]	'	'
Assets	'	'
Total cash and cash equivalents	21,376	13,399
Level 2 [Member] | Cash And Cash Equivalents [Member] | Commercial Paper [Member]	'	'
Assets	'	'
Total cash and cash equivalents	21,376	13,399
Level 2 [Member] | Investments [Member]	'	'
Assets	'	'
Total investments	77,475	86,166
Level 2 [Member] | Investments [Member] | Commercial Paper [Member]	'	'
Assets	'	'
Total investments	48,578	61,264
Level 2 [Member] | Investments [Member] | Corporate Debt Securities [Member]	'	'
Assets	'	'
Total investments	8,599	8,629
Level 2 [Member] | Investments [Member] | Asset Backed Securities [Member]	'	'
Assets	'	'
Total investments	20,298	16,273
Level 3 [Member]	'	'
Assets	'	'
Total assets measured at fair value	'	'
Liabilities	'	'
Total liabilities measured at fair value	549	549
Level 3 [Member] | Financing Derivative [Member]	'	'
Liabilities	'	'
Total liabilities measured at fair value	549	549
Level 3 [Member] | Cash And Cash Equivalents [Member]	'	'
Assets	'	'
Total cash and cash equivalents	'	'
Level 3 [Member] | Cash And Cash Equivalents [Member] | Cash And Money Market Funds [Member]	'	'
Assets	'	'
Total cash and cash equivalents	'	'
Level 3 [Member] | Cash And Cash Equivalents [Member] | Commercial Paper [Member]	'	'
Assets	'	'
Total cash and cash equivalents	'	'
Level 3 [Member] | Investments [Member]	'	'
Assets	'	'
Total investments	'	'
Level 3 [Member] | Investments [Member] | Commercial Paper [Member]	'	'
Assets	'	'
Total investments	'	'
Level 3 [Member] | Investments [Member] | Corporate Debt Securities [Member]	'	'
Assets	'	'
Total investments	'	'
Level 3 [Member] | Investments [Member] | Asset Backed Securities [Member]	'	'
Assets	'	'
Total investments	'	'

Summary_Of_Significant_Account5

Summary Of Significant Accounting Policies (Estimated Fair Value And Carrying Value Of Notes) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Feb. 05, 2013
In Thousands, unless otherwise specified
Summary Of Significant Accounting Policies [Abstract]	'	'	'
Long-term notes payable, Fair Value	$14,551	$14,551	'
Long-term notes payable, Carrying Value	$13,525	$13,347	$12,800

Summary_Of_Significant_Account6

Summary Of Significant Accounting Policies (Computation Of Basic And Diluted Net Loss Per Share) (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Numerator:	'	'
Net loss	($18,886)	($21,104)
Denominator:	'	'
Weighted average shares used in computation of basic and diluted net loss per share	67,861	57,372
Basic and diluted net loss per share	($0.28)	($0.37)

Summary_Of_Significant_Account7

Summary Of Significant Accounting Policies (Anti-dilutive Excluded From Computation Of Diluted Net Loss Per Share) (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Options Outstanding [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Stock excluded from the computation of diluted net loss per share	15,714	13,741
Warrants To Purchase Common Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Stock excluded from the computation of diluted net loss per share	5,500	5,504

Contractual_Revenue_Details

Contractual Revenue (Details) (USD $)	1 Months Ended	3 Months Ended
	Sep. 30, 2013	Mar. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Deferred revenue, revenue recognized	'	$1,700,000
Deferred revenue	'	31,600,000
Additional payment based upon achievements of milestones	40,000,000	0
Roche Agreement [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Non-refundable upfront payment	$35,000,000	'

Cash_Cash_Equivalents_And_Inve2

Cash, Cash Equivalents And Investments (Summary Of Cash And Cash Equivalents And Investments) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	$118,718	$112,514
Gross unrealized gains	27	28
Gross unrealized losses	-9	-14
Fair Value	118,736	112,528
Cash And Cash Equivalents [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	41,260	26,361
Gross unrealized gains	1	1
Fair Value	41,261	26,362
Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	77,458	86,153
Gross unrealized gains	26	27
Gross unrealized losses	-9	-14
Fair Value	77,475	86,166
Cash And Money Market Funds [Member] | Cash And Cash Equivalents [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	19,885	12,963
Fair Value	19,885	12,963
Commercial Paper [Member] | Cash And Cash Equivalents [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	21,375	13,398
Gross unrealized gains	1	1
Fair Value	21,376	13,399
Commercial Paper Not Included With Cash And Cash Equivalents [Member] | Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	48,575	61,252
Gross unrealized gains	4	13
Gross unrealized losses	-1	-1
Fair Value	48,578	61,264
Corporate Debt Securities [Member] | Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	8,589	8,620
Gross unrealized gains	13	12
Gross unrealized losses	-3	-3
Fair Value	8,599	8,629
Asset Backed Securities [Member] | Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	20,294	16,281
Gross unrealized gains	9	2
Gross unrealized losses	-5	-10
Fair Value	$20,298	$16,273

Cash_Cash_Equivalents_And_Inve3

Cash, Cash Equivalents And Investments (Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments) (Details) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Cash, Cash Equivalents And Investments [Abstract]	'
Due in one year or less	$71,947
Due after one year through five years	26,904
Total	$98,851

Balance_Sheet_Components_Compo

Balance Sheet Components (Components Of Inventory) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Purchased materials, net	$2,644	$3,019
Work in process, net	4,003	4,012
Finished goods, net	1,654	3,019
Inventory, net	$8,301	$10,050

Debt_Details

Debt (Details) (USD $)	0 Months Ended	3 Months Ended
	Feb. 05, 2013	Mar. 31, 2014	Dec. 31, 2013
Line of Credit Facility [Line Items]	'	'	'
Principal amount of notes	$14,100,000	'	'
Cash and cash equivalent minimum amount quarterly required	'	2,000,000	'
Weighted average market yield of derivative	'	20.40%	'
Fair value of the financing derivative	1,000,000	500,000	500,000
Purchase shares of common stock	5,500,000	5,500,000	'
Common stock aggregate exercise price	$2.63	'	'
Fair value of the warrants	6,400,000	'	'
Allocation of notes calculated on a relative fair value basis	20,500,000	'	'
Long-term notes payable, Carrying Value	12,800,000	13,525,000	13,347,000
Additional discount allocated to the warrants	7,700,000	'	'
Expected maturity period	'7 years	'	'
Effective interest rate	20.60%	'	'
Deerfield Promissory Notes [Member]	'	'	'
Line of Credit Facility [Line Items]	'	'	'
Principal amount of notes	$20,500,000	'	'
Deerfield promissory notes simple interest	8.75%	'	'

Stockholders_Equity_And_ShareB2

Stockholders' Equity And Share-Based Compensation (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
	item
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Proceeds from Issuance of Common Stock, Net of Issuance Costs	$20,646,000	$8,655,000
Number of equity compensation plans	3	'
ESPP [Member]	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Shares issued	1,048,604	733,111
Common stock reserved for issuance	276,903	'
At The Market Offering [Member]	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Shares issued	3,000,000	'
Average common stock price per share	$7.12	'
Common stock available for future sales	$17,900,000	'

Stockholders_Equity_And_ShareB3

Stockholders' Equity And Share-Based Compensation (Summary Of Stock Option Activity) (Details) (Stock Option [Member], USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Additional shares reserved, Shares available for grant	3,977,000	'
0.20 - 16.00 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Balances, December 31, 2012, Shares available for grant	3,912,000	'
Balances, December 31, 2013, Shares available for grant	6,081,000	3,912,000
Balances, December 31, 2012, Number of shares	14,070,000	'
Balances, December 31, 2013, Number of shares	15,714,000	14,070,000
Exercise price, lower range	$0.20	$0.20
Exercise price, upper range	$16	$16
Balances, December 31, 2012, Weighted average exercise price per share	$4.81	'
Balances, December 31, 2013, Weighted average exercise price per share	$5.04	$4.81
5.98 - 7.05 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options granted, Shares available for grant	-1,898,000	'
Options granted, Number of shares	1,898,000	'
Exercise price, lower range	$5.98	'
Exercise price, upper range	$7.05	'
Options granted, Weighted average exercise price per share	$6.61	'
0.70 - 6.96 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options exercised, Shares available for grant	'	'
Options exercised, Number of shares	-164,000	'
Exercise price, lower range	$0.70	'
Exercise price, upper range	$6.96	'
Options exercised, Weighted average exercise price per share	$2.96	'
1.16 - 12.74 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options canceled, Shares available for grant	90,000	'
Options canceled, Number of shares	-90,000	'
Exercise price, lower range	$1.16	'
Exercise price, upper range	$12.74	'
Options canceled, Weighted average exercise price per share	$6.70	'

Stockholders_Equity_And_ShareB4

Stockholders' Equity And Share-Based Compensation (Schedule Of Stock-Based Compensation Expense) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	$2,270	$2,746
Cost Of Revenue [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	141	136
Research And Development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	886	1,217
Sales, General And Administrative [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	$1,243	$1,393

Stockholders_Equity_And_ShareB5

Stockholders' Equity And Share-Based Compensation (Schedule Of Fair Value Of Employee Stock Options (Details)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Expected term in years	'6 years 1 month 6 days	'6 years 1 month 6 days
Expected volatility	70.00%	65.00%
Risk-free interest rate	1.90%	1.10%
Dividend yield	'	'
ESPP [Member]	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Expected volatility	70.00%	70.00%
Risk-free interest rate, minimum	0.10%	0.10%
Risk-free interest rate, maximum	-0.30%	-0.30%
Dividend yield	'	'
ESPP [Member] | Minimum [Member]	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Expected term in years	'6 months	'6 months
ESPP [Member] | Maximum [Member]	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Expected term in years	'2 years	'2 years